FRX Forest Road Acquisition Corp

NEW YORK, Oct. 26 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX), an international pharmaceutical manufacturer and marketer, and its partner H. Lundbeck A/S of Denmark, announced that the Federal District Court, District of Delaware has today rescheduled the start of its pending patent litigations trial regarding Lexapro(R) (escitalopram oxalate) from December 5, 2005 to March 15, 2006. A pretrial conference has been scheduled for February 7, 2006. Forest and Lundbeck remain confident in the strength and validity of the Lexapro patent. (Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products and the risk factors listed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2005 and on Form 10-Q for the period ended June 30, 2005. http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO DATASOURCE: Forest Laboratories, Inc. CONTACT: Charles E. Triano, Vice President - Investor Relations, of Forest Laboratories, Inc., +1-212-224-6714, Web site: http://www.frx.com/

Copyright